Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Theta Burst Stimulation in the Management of Methamphetamine Use Disorder in Indonesia

NCT: NCT07399431 · COMPLETED

NCT IDNCT07399431
StatusCOMPLETED
Start Date2026-03-23
Completion2026-06-12
SponsorIndonesia University (OTHER)
First posted
Last updated

Brief Summary

Methamphetamine use disorder (MUD) remains a major public health concern in Indonesia, with limited effective treatment options and high relapse rates. Theta Burst Stimulation (TBS) has emerged as a promising adjunctive intervention for reducing craving and improving clinical outcomes. This trial aims to evaluate the efficacy and safety of TBS for MUD. A RCT of 20 subjects was conducted to evalute the efficacy and safety of TBS as an adjunctive treatment to CBT in managing MUD.

Frequently Asked Questions

What is Theta Burst Stimulation in the Management of Methamphetamine Use Disorder in Indonesia?

Theta Burst Stimulation in the Management of Methamphetamine Use Disorder in Indonesia is a clinical trial registered under NCT07399431. Current status: COMPLETED.

What is the status of NCT07399431?

The current status of NCT07399431 (Theta Burst Stimulation in the Management of Methamphetamine Use Disorder in Indonesia) is: COMPLETED.

When did Theta Burst Stimulation in the Management of Methamphetamine Use Disorder in Indonesia start?

Theta Burst Stimulation in the Management of Methamphetamine Use Disorder in Indonesia started on 2026-03-23.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.